Anifrolumab: the new frontier in the treatment of genetic interferonopathies

RMD Open. 2024 Sep 23;10(3):e004780. doi: 10.1136/rmdopen-2024-004780.

Marie-Louise Frémond^{1

2}, Clémence David², Christophe Richez^{3

4}

¹ Department of Paediatric Hematology-Immunology and Rheumatology, Centre de Référence des Rhumatismes inflammatoires, maladies Auto-immunes et Interféronopathies Systémiques de l'Enfant RAISE, Necker-Enfants Malades Hospital, AP-HP, Paris, France [email protected] [email protected].
² Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France.
³ Department of Rheumatology, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpital Pellegrin, Bordeaux, France [email protected] [email protected].
⁴ ImmunoConcEpT, CNRS UMR 5164, University Bordeaux, Bordeaux, France.

No abstract available

Keywords: autoimmune diseases; inflammation; therapeutics.

Publication types